Neurofilaments for NEDA Assessing in MS
What it found
The trial ended early for another reason (see below).
Reason given: Under recruitment
This trial finished 4 years ago. We found no results in the registry or in any paper that cites it.
What was tested
Treatment tested
- Alemtuzumab
CAMPATH-1 antigen inhibitor
What it measured
Main measures
Blood and CSF neurofilaments in Alemtuzumab patients over 24months
2 years
Blood or spinal fluid markers
Other measures (3)
Overall clinical response based on neurofilament response
2 years
Blood or spinal fluid markersNeurofilament status and association with clinical and MRI markers of disease activity.
2 years
MRI lesionsBlood or spinal fluid markersLongitudinal assessment of other biomarkers of inflammation & plasticity
2 years
Blood or spinal fluid markers
Who could take part
Relapsing MS · 18 to 55
Inclusion Criteria: 1. Diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS). 2. Age 18-55 years. 3. EDSS score between 0-5.5. 4. Commencing Alemtuzumab therapy at Neurology Infusion and Planned Investigation Unit, The Royal London Hospital, Ward 11D Exclusion Criteria: 1. A diagnosis of Secondary Progressive MS (SPMS) or other forms of progressive MS. 2. Those unable to comply with study requirement
As registered. Criteria can change, so ask the trial team or your neurologist.
About this trial
In the sponsor's words
Goal is to evaluate the achievement of biological NEDA as demonstrated by a drop in neurofilament levels in MS patients commencing Alemtuzumab therapy as part of their MS management.
Loading reviews and guidelines…
Related trials
- HiHat
Phase 2 · Recruiting
Still running
- MS700568_0198
Phase 4 · Not yet recruiting
Still running
- Cladribine Tablets Level of Response Predictors in Clinic…
Running, not recruiting
Still running
- ADAs to Alemtuzumab
Completed
No result found
- A Study to Learn More About The Safety of Diroximel Fumar…
Running, not recruiting
Still running
- COAST
Phase 2 · Stopped early
Stopped early
History
Started
Aug 2017
Main results due
Jan 2022
Finished
Jan 2022
Assembled by software from public sources and not checked by people. Each record links to its source. Report an error